Ph1 study of ABBV-383 in subjects with relapsed or refractory MM
Phase I Clinical Trial
A Multicenter Phase 1b Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma (M24-108)